ABOS
Acumen Pharmaceuticals Poised for Breakthroughs in Alzheimer's Treatment
Acumen Pharmaceuticals, a leading player in the field of Alzheimer's disease treatment, has marked significant progress in its lead program, sabirnetug, in the fourth quarter of 2025. In a conference call to discuss their business update and financial results for the year ended December 31, 2025, company executives